Edwin M. O'Connor

Mr. O’Connor’s recent financings, initial public offerings and follow-on offerings include:

• Centessa Pharmaceuticals in its $379.5 million initial public offering 
• Phreesia in its $245.3 million and $174 million follow-on offerings and $167 million initial public offering 
• argenx NV in its $1.15 billion, $862 million, $300 million and $266 million follow-on offerings, and $114 million initial public offering
• BeiGene in its $2.08 billion registered direct offering, $340 million, $800 million, $201 million and $200 million follow-on offerings, and $158 initial public offering 
• Galecto in its $85 million initial public offering and $64 million cross over financing 
• Praxis Precision Medicines in its $190 million initial public offering
• C4 Therapeutics in its $209.76 million initial public offering
• Saniona in its $65 million cross over financing
• Hillhouse Capital as lead investor in the $418 million private placement of I-Mab 
• BeiGene in its $2.7 billion global strategic collaboration with Amgen
• Ascentage Pharma in its $53 million initial public offering on the Hong Kong Stock Exchange
• Deciphera Pharmaceuticals in its $127 million initial public offering
• Inotek Pharmaceuticals Corporation in its sale to Rocket Pharmaceuticals, $50 million offering of convertible senior notes, $69 million follow-on offering, $20 million offering of convertible senior notes, and $40 million initial public offering
• Moderna in its $604 million initial public offering
• Voyager Therapeutics in its $70 million initial public offering
• The underwriters in Valneva’s $107.6 million initial public offering
• The underwriters in Olo’s $517.5 million initial public offering
• The underwriters in Finch Therapeutics’ $127.5 million initial public offering
• The underwriters in Decibel Therapeutics’ $127 million initial public offering
• The underwriters in Sensei Biotherapeutics’ $133 million initial public offering
• The underwriters in Opthea’s $128.2 million initial public offering
• The underwriters in Albireo’s $160 million follow-on offering
• The underwriters in Freeline Therapeutics’ $158 million initial public offering
• The underwriters in Royalty Pharma’s $2.5 billion initial public offering
• The underwriters in Syndax Pharmaceuticals’ $143.8 million and $115 million follow-on offerings
• The underwriters in Centogene’s $56 million initial public offering
• The underwriters in follow-on offerings for DBV Technologies
• The underwriters in Genfit’s $135 million initial public offering
• The underwriters in PhaseBio Pharmaceuticals’ $46 million initial public offering
• The underwriters in Evelo Biosciences’ $85 million initial public offering
• The underwriters in Arsanis’ $40 million initial public offering 
• The underwriters in Altair Engineering’s $200 million convertible notes offering, $196 million follow-on offering and $156 million initial public offering
• The underwriters in G1 Therapeutics’ $180 million and $100 million follow-on offerings, and $105 million initial public offering
• The underwriters in Ovid Therapeutics’ $75 million initial public offering
• The underwriter in BeyondSpring’s $54 million initial public offering
• The underwriters in Reata Pharmaceuticals' $60.5 million initial public offering
• The underwriters in Oncobiologics' $35 million initial public offering
• The underwriters in Trinseo’s $190 million initial public offering*
• The underwriters in Paycom Software’s $100 million initial public offering*

As Vice President in Goldman Sachs’ Investment Banking Division, Mr. O’Connor advised on several initial public offerings, including:

• Cornerstone OnDemand’s $137 million initial public offering
• RPX’s $160 million initial public offering
• Gigamon’s $128.5 million initial public offering
• Jive’s $120 million initial public offering
• Palo Alto Network’s $260 million initial public offering

* Denotes experience prior to joining Goodwin.